News

Outreach initiative supports awareness of agitation and patient engagement as enrollment approaches completion

Behavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer’s agitation study

Authorization provides regulated capability to evaluate emerging therapeutic approaches alongside Phase 2 CALMA trial approaching completion

POTOMAC, Maryland – April 14, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announced that it has approximately 80% patient enrollment in its Phase 2 CALMA clinical trial

POTOMAC, MARYLAND – April 08, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company with its lead program currently in a Phase 2 CALMA clinical trial evaluating IGC-AD1 for Alzheimer’s-related agitation today announced that Ascendiant Capital Markets has

POTOMAC, MARYLAND – April 07, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing innovative treatments for Alzheimer’s disease, today announced the activation of a new clinical trial site

Strategic Pivot to Pure-Play Biotech

POTOMAC, Maryland – March 18, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics for Alzheimer’s disease, today announced it will demonstrate its Agentic Harmonization Assistant

POTOMAC, MARYLAND – February 26, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics for Alzheimer’s disease, today announced the filing

POTOMAC, MARYLAND – February 24, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that Ascendiant Capital Markets has issued an updated equity research report